Evidence map›Paper›PMID 32157125›Full record

ArticleScientific reports2020

Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus.

Michael A Smith, Chia-Chien Chiang, Kamelia Zerrouki, Saifur Rahman, Wendy I White, Katie Streicher, William A Rees, Adam Schiffenbauer, Lisa G Rider, Frederick W Miller and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. CD8International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Michael A SmithAstraZeneca, Gaithersburg, MD, USA.
Chia-Chien ChiangAstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0002-2110-8278
Kamelia ZerroukiAstraZeneca, Gaithersburg, MD, USA.
Saifur RahmanAstraZeneca, Gaithersburg, MD, USA.
Wendy I WhiteAstraZeneca, Gaithersburg, MD, USA.
Katie StreicherAstraZeneca, Gaithersburg, MD, USA.
William A ReesAstraZeneca, Gaithersburg, MD, USA.
Adam SchiffenbauerEnvironmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.
Lisa G RiderEnvironmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.
Frederick W MillerEnvironmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.
Zerai MannaLupus Clinical Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Sarfaraz HasniLupus Clinical Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Mariana J KaplanSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-2968-0815
Richard SiegelImmunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Dominic SinibaldiAstraZeneca, Gaithersburg, MD, USA. dominic.sinibaldi@astrazeneca.com.
Miguel A SanjuanAstraZeneca, Gaithersburg, MD, USA.
Kerry A CaseyAstraZeneca, Gaithersburg, MD, USA. kerry.casey@bms.com.ORCID 0000-0001-7194-8585
AstraZeneca (United States) · USNational Institutes of Health · USAstraZeneca (Japan) · JPAstraZeneca (Netherlands) · NL

Funding

Environmental/genetic Risk Factors and Pathogenesis of Autoimmune DiseaseZIAES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$34.6M
Systemic AutoimmunityZIAAR041199 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI KAPLAN, MARIANA · 2014 to 2025
$32.5M
6 · The paper itself

Abstract

Type I interferon (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked via IFN-inducible transcripts in blood. Here, we examined whether measurement of circulating proteins, which enter the bloodstream from inflamed tissues, also offers insight into global IFN activity. Using a novel protocol we generated 1,132 aptamer-based protein measurements from anti-dsDNA

Indexed as

Antibodies, Monoclonal, HumanizedAutoantibodiesBiomarkersGene Expression ProfilingHumansInterferon Type ILupus Erythematosus, SystemicProteomeSeverity of Illness IndexanifrolumabAntibodies, Monoclonal, HumanizedAutoantibodiesBiomarkersInterferon Type IProteome

Identifiers

PMID32157125
PMCPMC7064569
OpenAlexW3012113304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.